PV Bulletin

Introduction of Mandatory Annual Safety Report (ASR) Module in CTIS

The EMA announces a new ASR module in the Clinical Trials Information System (CTIS), becoming the mandatory channel for ASR submissions for clinical trials under Regulation (EU) No 536/2014.

Primary source: Download medicine data | European Medicines Agency (EMA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

The ASR module in the CTIS becomes mandatory for submitting Annual Safety Reports for clinical trials, requiring compliance with new submission protocols established under Regulation (EU) No 536/2014.

Why it matters

This change impacts clinical trial sponsors as they are required to adapt their safety reporting workflows to ensure compliance with the new mandatory channel for ASR submissions.

Action needed

Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
new
Publication date
12 June 2026
Policy change
Announcement and technical overview of a new Annual Safety Report (ASR) module within the Clinical Trials Information System (CTIS). This module will become the mandatory channel for submitting and managing ASRs (equivalent to Development Safety Update Reports/DSURs) for clinical trials conducted under the Clinical Trials Regulation (Regulation (EU) No 536/2014).

Key changes

Introduction of a dedicated ASR safety module in CTIS; transition to a mandatory submission channel for ASRs; updated functionalities for managing safety reporting in the system; new process for accessing the CTIS training environment.

Affected workflows

ICSRCountry Compliance

Responsible groups

SponsorsPV OperationsClinical SafetyRegulatory Affairs

PV impact

Clinical trial sponsors must prepare for the mandatory transition to the CTIS ASR module for safety report submissions. PV operations and clinical safety teams will need to update internal SOPs, train staff on the new module's functionalities, and use the CTIS training environment to ensure compliance with the new submission workflow.

View regulator source

Source document details

Evidence and confidence

Confidence: highSource updated: Jun 12, 2026

Full briefing

Practical implication

Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.

The new ASR module will be the required method for submitting and managing Annual Safety Reports, analogous to Development Safety Update Reports (DSURs). This transition necessitates that clinical trial sponsors prepare by updating internal procedures and training staff on the new system functionalities.

What changed: The ASR module in the CTIS becomes mandatory for submitting Annual Safety Reports for clinical trials, requiring compliance with new submission protocols established under Regulation (EU) No 536/2014.

Why it matters: This change impacts clinical trial sponsors as they are required to adapt their safety reporting workflows to ensure compliance with the new mandatory channel for ASR submissions.

Practical implication: Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward